国泰海通证券股份有限公司 关于苏州和林微纳科技股份有限公司 部分募投项目结项并将节余募集资金 永久补充流动资金的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"、"保荐人"）作为苏州和 林微纳科技股份有限公司（以下简称"公司"、"和林微纳"）首次公开发行股票并 在科创板上市和 2021 年度向特定对象发行股票的持续督导机构，根据《证券发 行上市保荐业务管理办法》《上海证券交易所科创板股票上市规则》《上市公司募 集资金监管规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规 范运作》等法律、法规、规章、规范性文件以及《苏州和林微纳科技股份有限公 司章程》等有关规定，对和林微纳 2021 年度向特定对象发行股票部分募投项目 结项并将节余募集资金永久补充流动资金事项进行了核查，核查情况及核查意见 如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意苏州和林微纳科技股份有限公司向 特定对象发行股票注册的批复》（证监许可[2022]1105 号）文件核准，本公司向 特定投资者发行人民币普通股股票 9,874,453 股，发行价为每股 70.89 元，募集 资金总额人民币 699,999 ...

证券代码：688661 证券简称：和林微纳 编号：2025-052 一、 募集资金基本情况 根据中国证券监督管理委员会《关于同意苏州和林微纳科技股份有限公司向 特定对象发行股票注册的批复》（证监许可[2022]1105 号）文件核准，本公司 向特定投资者发行人民币普通股股票 9,874,453 股，发行价为每股 70.89 元，募 集资金总额人民币 699,999,973.17 元，扣除发行费用（不含税）10,481,485.32 元后，实际募集资金净额为人民币 689,518,487.85 元。上述募集资金已经天衡 会计师事务所（特殊普通合伙）出具的天衡验字（2022）00122《验资报告》验 证。公司已将上述募集资金存放于募集资金专项账户，公司及子公司与保荐机构、 存放募集资金的商业银行签署了《募集资金监管协议》。 二、募集资金投资项目情况 苏州和林微纳科技股份有限公司 关于部分募投项目结项并将节余募集资金永久补充 流动资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提醒： 本次结项的募集资金投资项 ...

证券代码：688661 证券简称：和林微纳 编号：2025-051 苏州和林微纳科技股份有限公司 第三届董事会第五次会议决议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 苏州和林微纳科技股份有限公司（以下简称"和林微纳"或"公司"）第三 届董事会第五次会议于 2025 年 12 月 18 日在苏州高新区普陀山路 196 号公司会 议室以现场及通讯相结合的方式召开。本次会议应出席董事 7 人，现场及通讯方 式出席董事 7 人，公司半数以上董事共同推举董事骆兴顺先生主持本次会议。本 次会议的召开符合《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）和《公司章程》的有关规定， 形成的决议合法、有效。 二、董事会会议审议情况 了《董事、高级管理人员薪酬管理制度》。 表决结果：同意 7 票，反对 0 票，弃权 0 票。 本议案已经公司第三届董事会薪酬与考核委员会会议审议通过，尚需提交股 东会审议。 具体内容详见公司同日在上海证券交易所网站（www ...

Group 1 - The company Helin Micro-Nano (SH 688661) announced that its third board meeting will be held on December 18, 2025, in Suzhou, combining in-person and remote participation [1] - The meeting will review documents including the proposal for the agenda [1] Group 2 - As of the report, Helin Micro-Nano has a market capitalization of 8.1 billion yuan [2]

Core Viewpoint - The company has approved the conclusion of a fundraising project and plans to permanently supplement its working capital with the remaining funds, amounting to approximately 55.68 million yuan [1]. Group 1 - The company held its third board meeting and the fourth audit committee meeting on December 18, 2025 [1]. - The board approved the conclusion of the "substrate-level testing probe R&D mass production project" under the fundraising project initiated in 2021 [1]. - The estimated surplus amount from the fundraising project is 55.68 million yuan [1].

第二条 本制度适用于以下人员： （一）董事会成员（含独立董事）； （二）高级管理人员：包括公司总经理、副总经理、财务负责人、董事会秘 书以及《公司章程》规定的其他高级管理人员。 董事、高级管理人员薪酬管理制度 第一章 总则 苏州和林微纳科技股份有限公司 第一条 为进一步完善苏州和林微纳科技股份有限公司（以下简称"公司"） 激励与约束机制，调动公司董事、高级管理人员工作积极性，根据《中华人民共 和国公司法》《上市公司治理准则》等有关法律、法规和规范性文件的规定及《苏 州和林微纳科技股份有限公司章程》（以下简称"《公司章程》"，结合本公司的实 际情况，制定本制度。 第五条 公司人力资源部、财务部配合董事会进行公司董事、高级管理人员 薪酬方案的具体实施。 第二章 标准和支付方式 第六条 公司董事的薪酬构成： 第三条 公司薪酬制度遵循以下原则： （一）公平、公正、公开原则； （二）责、权、利相结合的原则； （三）与公司长远发展相结合的原则； （四）短期与长期激励相结合的原则： （五）激励与约束相结合的原则。 第四条 公司董事、高级管理人员薪酬方案由董事会薪酬与考核委员会制定， 明确薪酬确定依据和具体构成。董事薪酬方案 ...

Core Viewpoint - The company has announced the completion of a fundraising project and plans to permanently allocate the surplus funds to working capital for daily operations [1] Group 1: Project Completion - The company held its third board meeting on December 18, 2025, to review and approve the completion of the "substrate-level testing probe R&D mass production project" [1] - The project has been completed and has reached the intended usable state as of December 15, 2025 [1] Group 2: Financial Details - The surplus funds from the completed project amount to 55.6827 million yuan [1] - The company intends to use the surplus funds to supplement its working capital permanently [1] - The actual amount will be based on the balance of the fundraising account on the day of the fund transfer [1]

Core Viewpoint - The company announced the completion of its substrate-level testing probe R&D project and plans to permanently allocate the surplus funds of 55.6827 million yuan to supplement its working capital [1] Group 1: Project Financials - The initial plan was to use 125 million yuan of raised funds for the project, but the actual investment amounted to 69.4513 million yuan [1] - The project generated interest and cash management income, net of fees, totaling 8.1178 million yuan [1] - There remains a payment obligation of 7.6238 million yuan related to the project [1] Group 2: Cost Management - The company achieved a surplus by strictly controlling costs and improving the efficiency of fund utilization [1] - The surplus funds will be used to support daily production and operational activities [1]

Group 1 - The core viewpoint of the article highlights the target price increases for several listed companies as of December 15, with notable gains in the pharmaceutical and automation sectors [1][5]. - The companies with the highest target price increases include Zejing Pharmaceutical at 35.00%, Zoli Pharmaceutical at 34.58%, and Genesis at 27.40%, indicating strong bullish sentiment in the chemical pharmaceutical, traditional Chinese medicine, and automation equipment industries respectively [1][5]. - A total of 21 listed companies received broker recommendations on December 15, with Zoli Pharmaceutical receiving the most recommendations at 5, while companies like Tiandi Technology and Changbao Co. received 1 recommendation each [6]. Group 2 - On December 15, brokers initiated coverage on 7 companies, with Changbao Co. receiving an "Accumulate" rating from China Merchants Securities, Genesis receiving a "Outperform" rating from China International Capital Corporation, and SAIC Motor receiving a "Buy" rating from Aijian Securities [3][7]. - The newly covered companies include Changbao Co. in the special steel industry, Genesis in the automation equipment sector, and SAIC Motor in the passenger vehicle market, indicating a diverse range of industries being targeted for investment [4][8].

Core Insights - On December 15, 2023, brokerage firms provided target prices for listed companies, with notable increases for Zejing Pharmaceutical, Zoli Pharmaceutical, and Genesis, showing target price increases of 35.00%, 34.58%, and 27.40% respectively, across the chemical pharmaceuticals, traditional Chinese medicine, and automation equipment industries [1][2]. Group 1: Target Price Increases - Zejing Pharmaceutical received a target price increase of 35.00%, with a latest closing price of 135.00 yuan [2]. - Zoli Pharmaceutical's target price increased by 34.58%, with a closing price of 17.18 yuan [2]. - Genesis saw a target price increase of 27.40%, with a closing price of 11.30 yuan [2]. Group 2: Brokerage Recommendations - A total of 21 listed companies received brokerage recommendations on December 15, with Zoli Pharmaceutical receiving the highest number of recommendations at 5 [3]. - Other companies like Tiandi Technology and Changbao Co. received 1 recommendation each [3]. Group 3: First Coverage Ratings - On December 15, 7 companies received initial coverage from brokerages, including Changbao Co. with an "Accumulate" rating from China Merchants Securities [4]. - Genesis received a "Outperform Industry" rating from China International Capital Corporation [4]. - SAIC Motor was rated "Buy" by Aijian Securities [4].